Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 27 of 35.
May 2014
13 May · Dividend
Dr. Reddy's Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 13, 2014 have recommended a final dividend of Rs.18/- (360%) per equity share of Rs.5/- face value, for the financial year 2013-14..13 May · Dividend
Dr. Reddy's Laboratories Limited has informed the Exchange that the dividend on equity shares, if declared by the shareholders at the ensuing Annual Genera! Meeting, will be credited / despatched on or after August 07, 2014.13 May · Consolidated Result Updates - IFRS
Apr 2014
11 Apr · Board meeting
8 Apr · Results
Dr. Reddy's Laboratories Limited has informed the Exchange that the Company will announce and publish the audited annual financial results of the Company for the year ended March 31, 2014 instead of unaudited/audited quarterly financial results for the quarter ended March 31, 2014. the above referred audited annual financial results of the Company for the year ended March 31, 2014 would be announced within 60 days from the end of the relevant financial year.
Mar 2014
Feb 2014
19 Feb · Redemption
Members of the Exchange are hereby informed that the trading in the Non-convertible Debentures (Symbol DRREDDY, Series N1) of Dr. Reddy's Laboratories Limited shall be suspended w.e.f. February 20, 2014 (i.e. closing hours of trading on February 19, 2014) on account of Redemption.11 Feb · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2013 as follows: Net Sales of Rs. 254711 lacs for the quarter ending on 31-DEC-2013 against Rs. 269182 lacs and Rs. 213725 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively. Net Profit / (Loss) of Rs. 62317 lacs for the quarter ending on 31-DEC-2013 against Rs. 77338 lacs and Rs. 34664 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively.
Jan 2014
20 Jan · Business
Dr. Reddy's Laboratories Limited has informed the Exchange that pursuant to Company's Employees Stock Option Scheme, 2002, the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 9,133 equity shares of Rs.5/- each of the Company, fully paid up, on January 17, 2014, to Employees on exercise of their Stock Options.
Oct 2013
4 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2013.
Sep 2013
4 Sep · Business
Dr. Reddy's Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation committee of the Board of Directors of the Company has allotted 31,216 equity shares of Rs.5/- each of the Company, fully paid up, on September 03, 2013, to Employees on exercise of their Stock Options as per the following details: (a) 27,903 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002. (b) 3,313 equity shares of Rs.5/- each underlying 3,313 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007.
Aug 2013
Jul 2013
Jun 2013
May 2013
20 May · Meeting
Dr. Reddy's Laboratories Limited has informed the Exchange that the Company has fixed Book Closure from July 16, 2013 to July 19, 2013 (both days inclusive) for the purpose of Annual General Meeting of the shareholders of the Company and for determing the sharehoders who would be entitled for the payment of dividend if declared at the forthcoming Annual General Meeting, scheduled to be held on July 31, 2013.15 May · Updates
Dr. Reddy's Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company in their meeting held on May 13, 2013 has granted 261,650 stock options, exercisable at par value of Rs. 5/- under "Dr. Reddy's Employees Stock Option Scheme, 2002" and 45,040 stock options, exercisable at par value of Rs. 5/- under "Dr. Reddy's Employees ADR Stock Option Scheme, 2007" to the employees of the Company. The grant of above stock options is in line with SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999, as amended and as per the terms of the Stock Option Schemes.14 May · Dividend
Dr. Reddy's Laboratories Limited has informed the Exchange that the dividend on equity shares, if declared by the shareholders at the ensuing Annual Genera! Meeting, will be credited / despatched on or after August 07, 2013.14 May · Consolidated Result Updates - IFRS
14 May · Dividend
Dr. Reddy's Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 14, 2013 have recommended a final dividend of Rs.15/- (300%) per equity share of Rs.5/- face value, for the financial year 2012-13.14 May · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2013 as follows: Net Sales of Rs. 807434 lacs for year ending on 31-MAR-2013 against Rs. 660378 lacs for the year ending on 31-MAR-2012. Net Profit / (Loss) of Rs. 126547 lacs for the year ending on 31-MAR-2013 against Rs. 91236 lacs for the year ending on 31-MAR-2012.14 May · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2013 as follows: Net Sales of Rs. 216090 lacs for the quarter ending on 31-MAR-2013 against Rs. 174871 lacs for the quarter ending on 31-MAR-2012. Net Profit / (Loss) of of Rs. 37815 lacs for the quarter ending on 31-MAR-2013 against Rs. 21179 lacs for the quarter ending on 31-MAR-2012.